Alnylam Pharma (ALNY) Misses Q3 EPS by 7c

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.21), $0.07 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $13.7 million versus the consensus estimate of $9.14 million.

At September 30, 2016, Alnylam had cash, cash equivalents and marketable securities, and restricted investments of $1.19 billion, as compared to cash, cash equivalents and marketable securities of $1.28 billion at December 31, 2015.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
• Is the global equity rally broadening? UBS weighs in